CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Taro Pharmaceuticals U.S.A., Inc. v. Perrigo UK FINCO Limited Partnership

1:15-cv-00859

Overview

Case Number 1:15-cv-00859
Filing Date 2015-09-22
Status Terminated
Termination Date 2016-05-23
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand Plaintiff

Parties

Defendant

Perrigo UK FINCO Limited Partnership NPE (University / Research)

Represented By

2 Attorneys Listed

John C. Phillips , Jr.

Phillips, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200

Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St

David A. Bilson

Phillips, Goldman, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200
Fax: +1 (302) 655-4210

Phillips, Goldman, McLaughlin & Hall, P.A., 1200 North Broom Street

Plaintiff

Taro Pharmaceuticals North America, Inc. Operating Company

Represented By

1 Attorneys Listed

Dominick T. Gattuso

Heyman Enerio Gattuso & Hirzel LLP

Tel: +1 (302) 472-7311
Fax: +1 (302) 472-7301

300 Delaware Avenue, Suite 200, Wilmington, DE 19801

Taro Pharmaceuticals U.S.A., Inc. Operating Company

Represented By

4 Attorneys Listed

Charles B. Klein

Email: cklein@winston.com

Donald H. Mahoney , III

UNDELIVERABLE EMAIL 2/12/2019

Kevin E. Warner

Email: kwarner@winston.com

Dominick T. Gattuso

Heyman Enerio Gattuso & Hirzel LLP

Tel: +1 (302) 472-7311
Fax: +1 (302) 472-7301

300 Delaware Avenue, Suite 200, Wilmington, DE 19801

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 4 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 1 proceeding
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (4): πŸ‡ΊπŸ‡Έ US 🌐 PCT
Parallel Proceedings Across Jurisdictions (1 found):
U.S. Courts: 1
U.S. District Court 2014-07-28
1:14-cv-00989

Taro Pharmaceuticals USA Inc. v. Perrigo Israel Pharmaceuticals Ltd.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8277780
Stable liquid desoximethasone compositions with reduced oxidized impurity
Filed: 2006-05-26
Issued: 2012-10-02
Active (1.4 yrs remaining) +698d PTA
Expires: 2028-04-23
US8715624
Stable liquid desoximethasone compositions with reduced oxidized impurity
Filed: 2012-09-06
Issued: 2014-05-06
Active (5.8 yrs remaining)
Expires: 2032-09-06

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+698 days) / In re Cellect scrutiny applies.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Docket Entries

(39 total)
Pleading / Complaint

COMPLAINT filed with Jury Demand against Perrigo UK FINCO Limited Partnership - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1792402.) - filed by Taro Pharmaceuticals U.S.A., Inc., Taro Pharmaceuticals North America, Inc.. (Attachments: # 1 Civil Cover Sheet)(sec) (Entered: 09/22/2015)

Entry #1 • 2015-09-22
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (sec) (Entered: 09/22/2015)

Entry #2 • 2015-09-22
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 08/10/2015. Date of Expiration of Patent: 05/26/2026.Thirty Month Stay Deadline: 12/17/2016. (sec) (Entered: 09/22/2015)

Entry #3 • 2015-09-22
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 08/10/2015. Date of Expiration of Patent: 09/01/2028.Thirty Month Stay Deadline: 12/17/2016. (sec) (Entered: 09/22/2015)

Entry #4 • 2015-09-22
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Taro Pharmaceutical Industries Ltd. for Taro Pharmaceuticals North America, Inc., Taro Pharmaceuticals U.S.A., Inc. filed by Taro Pharmaceuticals North America, Inc., Taro Pharmaceuticals U.S.A., Inc.. (Gattuso, Dominick) (Entered: 09/22/2015)

Entry #5 • 2015-09-22
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc